The provision of ATMPs within the NHS is a relatively novel concept and it is anticipated that current NHS business case templates may not cover all core aspects that a management team would require to consider in order to support development of a new service. It has been recognised that ATMPs have higher associated costs and resource allocation associated with adoption compared to other medicinal products. These factors, along with the benefits and risks, should be thoroughly reviewed and justified within a business case in order for consideration and adoption to be successful.
Work Package 4 of the NA-ATTC, led by Ewan Morrison (NHS NSS) and Tom Chubb/Julie De-Almeida (Chiesi Ltd), have produced an advisory document to guide NHS Trusts/Boards on the key points to include in business cases to increase their success in securing the resources required in order to adopt these medicines.
The NHS business case guidance document details the key points for consideration, combined with examples provided by NA-ATTC clinical centres with previous experience of preparing business cases for ATMP provision. This document is now available on the Knowledge Hub of the ATTC website and is freely available to all NHS Clinical Site, Pharmaceutical Companies, small biotechnology developers and academic partners.